Coherus Oncology CHRS
NASDAQ CHRS
$0.99 -0.08 (-7.48%)
At close: Oct 16, 2026 · 4:00 PM EDT

Coherus Oncology (CHRS) EV to EBITDA (2019 - 2020)

Updated

Coherus Oncology's (CHRS) EV to EBITDA stood at 4.52 in Q4 2020, down 53.9% from 9.81 a year earlier but up 3.9% from the prior quarter.

Analysis

Coherus Oncology (CHRS) EV to EBITDA (2019 - 2020) Analysis & Trends

Starting with Q3 2019, Coherus Oncology's EV to EBITDA history includes 6 quarters.

  • Across earlier years, EV to EBITDA came in at 9.80 in FY2019.
  • Quarterly EV to EBITDA has ranged from 3.98 in Q2 2020 to 248.23 in Q3 2019 over the past five years.
  • Per Business Quant, the preceding three quarters came in at 4.35 (Q3 2020), 3.98 (Q2 2020) and 5.68 (Q1 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,122.91 Bn 1,091.50 Bn 19.71 Bn
2 Johnson & Johnson 615.09 Bn 533.62 Bn 17.26 Bn
3 AbbVie 504.75 Bn 477.86 Bn 12.70 Bn
4 Merck 360.18 Bn 314.55 Bn 12.21 Bn
5 Novartis Ag 292.05 Bn 256.04 Bn 11.24 Bn
6 Astrazeneca 256.09 Bn 229.78 Bn 12.86 Bn
7 Amgen 233.63 Bn 189.02 Bn 7.24 Bn
8 Gilead Sciences 194.49 Bn 168.69 Bn 6.22 Bn
9 Pfizer 168.35 Bn 114.99 Bn 10.94 Bn
10 Coherus Oncology 155.59 Mn -480.55 Mn 10.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 4.42
Sep 30, 2020 4.28
Jun 30, 2020 3.92
Mar 31, 2020 5.60
Dec 31, 2019 9.60
Sep 30, 2019 174.94
API Access

Coherus Oncology EV to EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=CHRS&period=max&api_key=YOUR_API_KEY